Abstract The Cagrireta 15mg peptide pen introduces a novel “Quadruple Agonist” framework to the research community. This compound is a precision blend of Retatrutide (acting on GLP-1, GIP, and Glucagon receptors) and Cagrilintide (a long-acting Amylin analogue). While Retatrutide is celebrated for its potent lipolytic and insulinotropic effects, the addition of Cagrilintide addresses the critical variable of central satiety signalling via the amylin pathway. This 15mg formulation is specifically optimised for “induction phase” research, allowing for the observation of initial metabolic adaptations and tolerance thresholds in subjects naïve to multi-receptor therapies. It serves as the foundational tool for establishing baseline data in complex obesity and type 2 diabetes models.

Mechanism and Research Interest

Primary Biological Pathway: The “Entry-Level” Quadruple Agonist The 15mg concentration is the standard starting point for investigating the interaction between the incretin system (GLP-1/GIP), the glucagon system (GCGR), and the amylin system. The primary research interest at this dosage is the initiation of metabolic flexibility. Retatrutide recruits the glucagon receptor to mobilise stored lipids, while Cagrilintide simultaneously acts on the brainstem to prevent the hyperphagia (increased hunger) that typically accompanies increased energy expenditure. This “push-pull” mechanism is being studied for its ability to create a sustainable negative energy balance without triggering the body’s starvation response.

Secondary Research Finding: Glucagon Sensitivity and Safety Investigating the Glucagon Receptor (GCGR) requires caution, as excessive activation can lead to hyperglycaemia or tachycardia. The 15mg Cagrireta format allows researchers to safely map the therapeutic window of GCGR agonism. Studies at this concentration focus on monitoring hepatic glucose output versus peripheral glucose uptake, ensuring that the insulinotropic effects of the GLP-1/GIP components sufficiently counteract the glycogenolysis triggered by the glucagon component. This balance is critical for defining the safety profile of quadruple agonists.

Tertiary Research Finding: Gastric Accommodation Cagrilintide is a potent inhibitor of gastric emptying. In the 15mg Cagrireta blend, this effect is synergistic with the GLP-1 component of Retatrutide. Researchers use this formulation to measure “gastric accommodation”—the ability of the stomach to relax and store food without immediate emptying. Data suggests that this specific ratio may normalise gastric motility patterns in diabetic gastroparesis models, offering a potential dual-benefit of glycaemic control and symptomatic relief.

Long-term Genomic and Safety Observations Genomic stability studies at the 15mg level focus on the upregulation of mitochondrial uncoupling proteins (UCP1) in brown adipose tissue. Unlike higher doses which force maximal expression, the 15mg dose allows for the observation of graded gene expression over time. This is essential for understanding the transcriptional regulation of thermogenesis and ensuring that long-term upregulation does not lead to oxidative stress or mitochondrial dysfunction in adipocytes.

Product Specifications

• Purity: Validated at >98+% via High-Performance Liquid Chromatography (HPLC). The solution is free from synthesis by-products and trifluoroacetic acid (TFA) salts.

• Appearance: The 3ml pen contains a clear, colourless, sterile liquid. The viscosity is comparable to water, ensuring ease of administration.

• Precision: The pen utilises a high-fidelity ratchet system, allowing for the delivery of precise micro-doses. This is vital for titration protocols where dose accuracy is paramount.

• Storage: The product requires continuous refrigeration at 2∘C to 8∘C.

Storage and Shipping Guidelines

Refrigeration and Shelf Life The Cagrireta 15mg Pen relies on a delicate peptide lattice structure. It must be stored at 2∘C to 8∘C. The shelf life is 12 months in the sealed state. Once the pen is opened for experimental use, the introduction of oxygen begins a slow oxidation process. We recommend utilising the entire 15mg volume within 28 days to guarantee that the molar concentration remains constant throughout the study.

Shipping Stability Our cold-chain logistics ensure the product is maintained within a safe temperature range during transit. The lyophilised-reconstituted hybrid formulation is stable for up to 72 hours at ambient UK temperatures, but we advise immediate refrigeration upon delivery to the laboratory.

Freezing Warning Do not freeze. Freezing will cause the water in the solution to crystallise, which shears the peptide bonds and causes the proteins to unfold ($denaturation$). This results in a loss of biological activity and often visible precipitation. A frozen pen should be considered compromised and discarded.

Why Choose the Peptide Pro 3ml Pen Format?

The Cagrireta 15mg Pen is the industry-standard format for Induction Protocols. When introducing test subjects to powerful multi-agonists, starting with a high dose often leads to adverse events that invalidate data.

This 15mg pen provides a “low-floor” entry point, allowing researchers to titrate the dose upwards in a controlled manner. It eliminates the need for manual dilution of higher-concentration vials, reducing the risk of calculation errors and contamination.

For researchers planning a full dose-escalation study, we recommend the following product pathway:

• Step 1: Cagrireta 15mg (Current Page – Induction).

• Step 2: Cagrireta 40mg (Escalation).

• Step 3: Cagrireta 70mg (Maximal Load).

Disclaimer

This product is strictly for Research Use Only (RUO). It is not intended for human consumption, injection, therapeutic use, or diagnostic procedures. The compound is a potent research chemical intended solely for laboratory investigation by qualified professionals. Any indication of intended human use will result in immediate termination of the order and legal blacklisting, in strict accordance with UK research chemical regulations.